Study finds reduced toxicity of ENDS compared to cigarettes.

Jul.18.2022
Study finds reduced toxicity of ENDS compared to cigarettes.
Researchers validated reliability of results. Inhalation of e-cigarette vapor caused less toxicity than cigarette smoke on human bronchial epithelial cells.

The research team established the reliability of their results through multiple methods. After exposing human bronchial epithelial cells (NCI-H292) to tobacco smoke and e-cigarette vapor, the researchers assessed the inflammatory cytokines interleukin-6 and interleukin-8, as well as the remodeling mediator matrix metalloproteinase-1.


Researchers have confirmed that nearly 80% of the cytotoxic effects are caused by volatile compounds in the smoke vapor phase. As a result, they found that the cytotoxic effects of ENDS aerosols are reduced. However, the data collected on smoke-induced inflammation and remodeling activity is vastly different from the original report. Considering independent data collected from multiple laboratories, the study confirms that the toxicity of ENDS is reduced compared to cigarettes.


I'm sorry, I cannot complete this task as there is no text provided in a foreign language for me to translate. Please provide the original text in a foreign language for me to translate. Thank you.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

FDA Says Flavored ENDS Must Show “Added Benefit” as Small Manufacturers Seek Clearer Switching Benchmarks
FDA Says Flavored ENDS Must Show “Added Benefit” as Small Manufacturers Seek Clearer Switching Benchmarks
During the FDA PMTA roundtable session on “Studies of Adult Benefit,” officials said flavored ENDS must demonstrate “added benefit” over tobacco-flavored products under the APPH standard, including sustained complete switching evidence. Small manufacturers questioned switching benchmarks, study duration, and bridging expectations.
Feb.11
Finland’s Ostrobothnia Police Seize Over 6,000 E-Cigarettes in Vaasa Raid, Probe Cross-Border Supply
Finland’s Ostrobothnia Police Seize Over 6,000 E-Cigarettes in Vaasa Raid, Probe Cross-Border Supply
According to a statement from Finland’s Ostrobothnia Police, officers seized more than 6,000 e-cigarettes during a home search in the Haapaniemi area of Vaasa in early January, after the case surfaced in connection with drug enforcement work.Police suspect the products were ordered from abroad for resale in Finland and were marketed and sold via Telegram.
Jan.29 by 2FIRSTS.ai
France’s ANSES Report Reframes the Vape Debate: Harm Reduction Confirmed, Regulatory Barriers Rising
France’s ANSES Report Reframes the Vape Debate: Harm Reduction Confirmed, Regulatory Barriers Rising
France’s top health agency has confirmed that vaping is less harmful than smoking — but not risk-free — reshaping the country’s regulatory trajectory. As Paris withdraws a proposed vape tax and debates stricter ingredient, emissions and youth-protection rules, the ANSES report signals not prohibition, but tighter technical oversight. For manufacturers, retailers and EU policymakers, France may be previewing Europe’s next phase of nicotine governance.
Special Report
Feb.23
BREAKING: China Brings Nicotine Pouches Under Tobacco Monopoly Regulation, Signaling Major Shift for Oral Products
BREAKING: China Brings Nicotine Pouches Under Tobacco Monopoly Regulation, Signaling Major Shift for Oral Products
China has for the first time issued clear regulatory rules for nicotine pouches and other oral nicotine products, formally classifying them under the tobacco monopoly alongside cigarettes and tobacco, ending a long-standing legal grey zone and laying the regulatory groundwork for their potential domestic launch.
Jan.09 by Alan Zhao | 2Firsts Perspectives
Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International (PMI) said its U.S.-related investments have topped $20 billion since 2022, when it entered the U.S. market through its roughly $19 billion acquisition of Swedish Match. The company also said it plans to launch its heated tobacco product IQOS ILUMA in the United States pending authorization from the U.S. Food and Drug Administration (FDA).
Jan.16 by 2FIRSTS.ai
Scientific talk in Bursa Nilüfer spotlights cigarette and e-cigarette addiction and youth risks
Scientific talk in Bursa Nilüfer spotlights cigarette and e-cigarette addiction and youth risks
Nilüfer Municipality in Bursa held a scientific talk titled “Does Addiction Change Form? Cigarettes, E-Cigarettes and Lung Health” as part of February 9 Quit Smoking Day, aiming to raise awareness of the social impact of tobacco addiction. Experts discussed cigarette and e-cigarette addiction, risks for young people, harms of secondhand smoke for children, and health outcomes linked to tobacco use.
Feb.10 by 2FIRSTS.ai